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The aim of this study was to assess the use of anti-asthmatic medications in Taiwanese
geriatric asthmatic patients. We used computerized prescription databases from the National
Health Insurance Program, Taiwan, and classified drugs according to the Anatomical
Therapeutic Chemical Classification System to analyze the patterns and extent of medication
use in people aged over 65 years, and the influence of physician specialty on the prescription
of anti-asthmatics. A total of 708,624 prescriptions for 226,018 patients were analyzed. Oral
medications were most often prescribed. Only 3.94% and 7.79% of patients were treated with
inhaled corticosteroids and inhaled short-acting β-agonists, respectively. Pulmonologists
prescribed significantly more inhaled anti-asthmatics, except for cromolyn, than other types
of physicians. More males than females were prescribed each category of anti-asthmatic
medications, except for ketotifen. In conclusion, physicians in Taiwan do not prescribe as
many inhaled anti-inflammatory agents for the treatment of asthma in the elderly as sug-
gested in international treatment guidelines.
Key Words: asthma, geriatric, medication
(Kaohsiung J Med Sci 2003;19:305–12)
Received: March 6, 2003 Accepted: March 27, 2003
Address correspondence and reprint requests to: Dr. Chun-
Yuh Yang, Graduate Institute of Public Health, Kaohsiung
Medical University, 100 Shih-Chuan 1st Road, Kaohsiung
80708, Taiwan.
E-mail: chunyuh@kmu.edu.tw
Asthma is a significant cause of morbidity and
healthcare utilization in the elderly. Asthma-related
hospitalizations of older patients have serious financial
consequences for the healthcare system [1]. Despite
improved medical technologies to manage asthma
and advances  in  the  unders tanding  o f  i t s
pathophysiology over the past decade, asthma-related
mortality in the elderly population continues to rise
[2]. The cause for this ever-increasing mortality is not
well understood. It is probably associated with the
under-recognition and under-treatment of asthma by
patients and physicians [3–5]. Contributory factors to
this underestimation may include the overlapping of
asthma symptoms with those of chronic obstructive
pulmonary disease (COPD), comorbidities such as
angina, and congestive heart failure that may mimic
asthma, and reduced subjective awareness of moderate
acute bronchoconstriction in old age [6–8].
Although the pathogenesis and therapeutic
response of asthma often differ between elderly and
younger patients, the basic principles of asthma therapy
for geriatric asthmatic patients are similar to those for
younger individuals. Treatment should adhere to the
stepwise recommendations, starting with inhaled
short-acting β-agonists (ISBAs) for mild intermittent
as thma,  and advanc ing  to  inc lude  inhaled
corticosteroids (ICSs) or oral corticosteroids (OCSs)
for mild to severe persistent asthma [9]. ICSs remain
the most effective agents to control inflammation in
the elderly. Anti-inflammatory agents are generally
© 2003 Elsevier. All rights reserved.
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underused and bronchodilators are overused [5,10–
15].
In Taiwan, the proportion and number of
individuals over 65 years old are steadily increasing.
It was estimated that, as of May 2002, people older
than 65 years in Taiwan accounted for 8.88% of the
population [16]. In terms of healthcare and its financing,
this is an issue of great concern. The burden to the
patients themselves, with regard to medical cost and
reduced quality of life, is high. The aging population
means that these problems can be expected to increase
in coming years. To date, little is known about
medication use among the asthmatic elderly in Taiwan.
The emergence of computerized prescription
databases allows population-based analysis of
individual drug use. Computerized individual
healthcare data, including diagnosis and prescription
data, have been available in Taiwan since the
implementation of the National Health Insurance
(NHI) Program in 1995. The data collected by the
Bureau of National Health Insurance (BNHI) in Taiwan
have provided unprecedented opportunities to
conduct population-based studies of healthcare
utilization. The purpose of this study was to determine
whether Taiwanese geriatric asthmatic patients receive
optimal pharmacotherapy.
MATERIALS AND METHODS
Data source
The NHI Program, which is a mandatory universal
health insurance program, was implemented in Taiwan
on March 1, 1995, and covers more than 95% of the
population (96.16% at the end of 2000) [17]. The BNHI
has become the sole buyer of health services. In 1997,
contracted medical care providers included about 96.5%
of hospitals and 89.5% of clinics [18].
Each month, contracted medical care providers
must file a computerized claim form to the BNHI. The
information on the computerized claim form includes
date, personal identification number (ID), age, sex,
medical care provider’s ID, prescribed drug’s
therapeutic code, diagnosis, and medical expense
claims.
Materials
The data files used in this study were retrieved from
the database of the BNHI, which manages the database
on behalf of the Department of Health. Under the
regulation of the Personal Electric Data Protection
Law, strict confidentiality guidelines were followed.
Both the personal and medical care provider’s IDs in
the database were scrambled. The study included all
prescriptions for asthma patients (ICD-9 493) who
were older than 65 years between  February 1 and June
30, 1998.
Prescription drugs were classified according to the
Anatomical Therapeutic Chemical Classification
System [19], allowing international comparison. They
included ISBAs and oral short-acting β-agonists
(OSBAs), inhaled ipratropium, methylxanthines, ICSs
and OCSs,  inhaled cromolyn,  and ketotifen.
Leukotriene modifiers and nedocromil were not
available in Taiwan during the study period.
Statistical analysis
The Chi-squared test was used to determine the odds
ratios for the different asthma treatments for females
compared with males and whether there were statisti-
cally significant differences in the percentages of pre-
scriptions for each anti-asthmatic medication among
different physician specialties. Analyses were performed
using the Statistical Analysis System software, version
6.12 (SAS Institute, Cary, NC, USA).
RESULTS
The study included 226,018 patients, of whom 89,553
(39.62%) were females and 136,465 (60.38%) were
males. In every age group, there were fewer female
than male patients. For females, the number of patients
declined gradually with increasing age from 65 years;
for males, there was a peak in the number of patients
at 72 years of age. A total of 708,624 prescriptions,
including 257,378 (36.32%) for female and 451,246 (63.68%)
for male patients, were analyzed. An average of 6.32
different drugs were used in each prescription, of
which an average of 1.32 items were anti-asthmatic
agents. Of the 4,478,262 prescribed drugs, 936,505
(20.91%) were anti-asthmatics.
Patterns and extent of medication use
Patients  were treated most  frequently  with
methylxanthines (49.70%). Only 3.94% and 0.04% of
patients received ICSs and cromolyn (inhaled anti-
inflammatory agents), respectively. As shown in Table 1,
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7.79% of patients were given ISBAs, while 44.03% of
patients received OSBAs. Significantly fewer females
than males were prescribed each category of anti-
asthmatic medication (p < 0.001). The only exception
was ketotifen, which was prescribed more often for
females than for males (p < 0.001).
The six most common anti-asthmatic regimens are
shown in Table 2. These regimens accounted for 29.89%
of all asthma prescriptions. It should be noted that
34.67% of prescriptions did not include any anti-asth-
matic agents. The highest percentage of prescriptions
(29.19%) contained only one anti-asthmatic item. These
included 14.50% with methylxanthine only, 10.90%
with OSBAs only, and 1.12% with OCSs only (Table 2).
A total of 19.10% of prescriptions contained two anti-
asthmatic drugs, and 17.04% of prescriptions con-
tained three or more anti-asthmatic drugs (Figure 1).
Influence of specialty on prescription of
anti-asthmatics
General internists accounted for more than half (55.61%)
of total prescriptions, followed by general practitioners
(20.24%) and family physicians (11.22%). However, pre-
scriptions from pulmonologists, the most desired spe-
cialist for treating asthma in the elderly, accounted for
only 3.33% of all prescriptions (Figure 2).
Even though pulmonologists contributed the fewest
prescriptions, a significantly higher proportion of their
prescriptions included inhaled anti-asthmatics
compared to those of other practitioners (p < 0.001).
However, there was no significant difference in the
use of cromolyn between pulmonologists and other
practitioners. Although 21.29% of prescriptions from
pulmonologists contained ISBAs and 19.87% included
ICSs, only 7.78% and 4.16% of general internists’
prescriptions included ISBAs and ICSs, respectively.
Pulmonologists were also more likely to prescribe
ipratropium (17.22%) and OCSs (22.37%). However,
they were less likely to use ketotifen, which only
accounted for 0.59% of their prescriptions (Table 3).
DISCUSSION
There were three main findings from our study: oral
anti-asthmatic agents are most often prescribed and
Table 1. Number and percentage of patients prescribed each category of anti-asthmatic medication
Drug Female (%) Male (%) Total (%) OR CI p value
ISBA 5,233 (5.84) 12,384 (9.07) 17,617 (7.79) 0.62 0.60–0.64 < 0.001
OSBA 36,525 (40.79) 62,987 (46.16) 99,512 (44.03) 0.80 0.79–0.82 < 0.001
Methylxanthine 41,617 (46.47) 70,720 (51.82) 112,337 (49.70) 0.81 0.79–0.82 < 0.001
Cromolyn 24 (0.03) 84 (0.06) 108 (0.04) 0.44 0.28–0.69 < 0.001
Ketotifen 2,848 (3.18) 3,973 (2.91) 6,821 (3.01) 1.10 1.04–1.15 < 0.001
ICS 2,695 (3.01) 6,211 (4.55) 8,906 (3.94) 0.65 0.62–0.68 < 0.001
Ipratropium 1,903 (2.12) 6,787 (4.97) 8,690 (3.84) 0.42 0.39–0.44 < 0.001
OCS 13,766 (15.37) 21,914 (16.06) 35,680 (15.79) 0.95 0.93–0.97 < 0.001
OR = odds ratio for different asthma treatments for females compared with males; CI = 95% confidence interval; ISBA = inhaled
short-acting β-agonist; OSBA = oral short-acting β-agonist; ICS = inhaled corticosteroid; OCS = oral corticosteroid.
Table 2. The six most common anti-asthmatic drug regimens
Regimen Number of prescriptions %
Methylxanthines only 102,762 14.50
OSBAs only 77,229 10.90
OSBAs + methylxanthines 13,287 1.88
OCSs only 7,903 1.12
OSBAs + OCSs 5,437 0.77
Methylxanthines + OCSs 5,104 0.72
OSBA = oral short-acting β-agonist; OCS = oral corticosteroid.
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ICSs are underused; pulmonologists prescribe signifi-
cantly more inhaled anti-asthmatics compared to other
practitioners (p < 0.001); and compared to males, fewer
females are prescribed each category of anti-asthmatic
medication.
Asthma is primarily regarded as an inflammatory
disease and current treatment strategies emphasize
ant i - inf lammatory medicat ions  as  f i rs t - l ine
maintenance or preventive therapy. The daily use of
anti-inflammatory medications, such as ICSs, is sug-
gested for all patients with mild to severe persistent
asthma [9]. Clinical trials and observational studies
have shown that ICS use in adequate amounts prevents
asthma symptoms, improves pulmonary physiologic
characteristics, and may reduce resource use for asthma
attacks [20–24]. There is growing evidence that the
persistence of airway inflammation predisposes to
airway remodeling, resulting in airway fibrosis and
Figure 1. Number of prescriptions according to the number of anti-asthmatic drug items per prescription.
Figure 2. Number of prescriptions by physician specialty.
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irreversible airflow obstruction. This risk increases
with the increase in the duration of asthma and the age
of patients. As a result, adequate treatment with anti-
inflammatory agents is particularly pertinent to the
elderly asthmatic population [25].
Anti-inflammatory agents continue to be underused
by patients and providers around the world [4,5,10].
Our study shows that inhaled anti-inflammatory
medications in Taiwan are underused in elderly
asthmatic patients to a greater extent than in other
countries. Asthma Insights and Reality in Asia Pacific
(AIRIAP) has reported that 11%, 14%, and 18% of all
asthma patients in Taiwanese samples would be
classified as having severe, moderate, and mild
persistent asthma, respectively [26]. Therefore,
according to current international guidelines, at least
43% of Taiwanese asthmatics should receive daily
inhaled anti-inflammatory therapy. However, only
3.94% and 0.04% of elderly asthmatics used ICSs and
cromolyn, respectively, in our study. These percent-
ages are far lower than those reported from other
countries. In the Cardiovascular Health Study, 30% of
geriatric asthma patients were prescribed ICSs [5]. In
a community survey, 22% of elderly patients with
asthma received ICSs [4]. Hartert et al also report that
of patients with moderate or severe asthma, 25% take
ICSs [10].
ISBAs should be used on an as-needed basis for
quick relief of bronchoconstriction. Due to their quick
onset and short duration of action, they are subject to
overuse that results in reduced efficacy. Their use has
also been associated with increased bronchial
hyperreactivity, central nervous system over-
stimulation, worsening asthma, and death [27,28].
Several recent studies have indicated excessive use of
ISBAs. Studies by Pinto Pereira et al [13] and Wolfenden
et al [14] found that 95% and 94.6% of patients,
respectively, took ISBAs. In our study, 7.79% of pa-
tients received ISBA therapy, so overuse of ISBA does
not currently appear to be an issue in Taiwan.
The role of ipratropium therapy in asthma is not
well defined. Ipratropium has a slower onset of action
and is a less potent bronchodilator than ISBAs [29].
Asthma and COPD frequently coexist in the elderly
[30]. Patients with COPD may respond to inhaled
ipratropium despite a lack of response to β-agonists
[31] .  In our study,  pulmonologists  included
ipratropium in 17.22% of their prescriptions. Pinto
Pereira et al indicate that ipratropium is selectively
used in elderly patients (35%), but rarely used in
asthmatic patients younger than 65 years [13].
In our study, 15.97% of elderly patients were taking
OCSs. This is slightly less than the 18% reported by
Enright et al [5]. OCSs have broad anti-inflammatory
effects and can substantially reduce the duration and
severity of an acute asthma exacerbation. However,
they can also cause several adverse side effects in the
elderly, including exacerbation of hypertension,
abnormalities in glucose metabolism, impaired
immune response, osteoporosis, and peptic ulcers.
OCSs are reserved for the small proportion of patients
with severe persistent asthma [9]. Efforts should be
made to minimize the extended use of OCSs in geriatric
asthmatics. These include using the lowest possible
dose and, perhaps, alternate-day therapy.
OSBAs have slow onset of action and are not suitable
for controlling acute asthma. They also cause more
side effects than ISBAs, such as tachycardia and
hypokalemia. They are not recommended by thera-
peutic guidelines [9]. Moreover, asthma and cardio-
vascular diseases frequently coexist in the elderly.
Table 1 shows that 44.03% of asthmatic patients in
Taiwan are prescribed OSBAs. OSBAs often take the
place of ISBAs because they are easy and convenient to
administer and, therefore, often used by the elderly.
The use of theophylline, the most common
Table 3. Percentage of prescriptions for each anti-asthmatic medication according to physician specialty
Physician specialty ISBA OSBA Methylxanthine Cromolyn Ketotifen ICS Ipratropium OCS
General practitioners 2.41 46.94 56.40 0.01 5.21 0.42 2.13 15.60
Family physicians 2.94 42.33 54.89 0.02 3.29 1.08 0.64 11.43
General internists 7.78 42.64 59.06 0.07 1.36 4.16 3.73 12.40
Pulmonologists 21.29* 47.34 63.35 0.05 0.59 19.87* 17.22* 22.37
ISBA = inhaled short-acting β-agonist; OSBA = oral short-acting β-agonist; ICS = inhaled corticosteroid; OCS = oral corticosteroid. *p < 0.001
compared to other practitioners.
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methylxanthine used in clinical practice, has been
reported to increase with age [20]. Hartert et al also
showed that theophylline was the most frequently
prescribed asthma drug (47%) [10], and as shown in
Table 1, methylxanthines are the most frequently
prescribed anti-asthmatic agent for the elderly in
Taiwan. Methylxanthines have a narrow therapeutic
index, more serious side effects than other anti-
asthmatics, and great potential for drug–drug
interactions. A large proportion of the elderly are usually
taking other drugs that may cause excessive serum
methylxanthine levels. However, a recent study has
shown that theophylline may have anti-inflammatory
effects at lower doses than those needed for
bronchodilation [32], and this has led to a re-evaluation
of its use in patients with asthma. In addition, a once-
or twice-daily slow-release oral preparation is
available. The use of oral theophylline may improve
patient compliance [33], which is particularly impor-
tant for elderly patients.
Oral anti-asthmatic agents are convenient
to administer, but have slower onset of action and
more potential for systemic side effects. Therefore, for
elderly asthmatics, inhaled medications should be
preferred whenever possible. The finding that significant
numbers of Taiwanese geriatric asthmatic patients are
taking OCSs and/or oral bronchodilators implies that
their asthmatic symptoms are poorly controlled.
However, in the elderly, neuromuscular-skeletal
disorders, weak or deformed hands, and intellectual
impairment may disturb inhaler use and discourage the
use of inhaled agents in this age group. Inappropriate or
insufficient patient education by healthcare providers
may also hamper the proper use of medication. Another
plausible explanation for the low level of use of inhaled
medications in Taiwan may be that patients lack
confidence in the effectiveness of inhalers.
Specialists are more likely than generalists to follow
contemporary guidelines for asthma management [34].
In our study, pulmonologists prescribed significantly
more ISBAs and ICSs compared to other practitioners
(p < 0.001); 21.29% of their prescriptions contained
ISBAs and 19.87% included ICSs. Studies show that
patients who receive care from primary-care physicians
are less likely to receive ICS therapy compared to
patients who receive care from specialists, i.e. under-
use of ICSs is more likely in patients of generalists than
in patients of pulmonologists [11,12]. Legorreta et al
indicate that specialists provide more thorough care
than primary physicians when treating patients with
asthma, and they also provide more information to
their patients about what to do to prevent or control an
asthma attack [35]. Wu et al also showed that patients
treated by pulmonologists were more likely to receive
ICS therapy and have better outcomes during the
ensuing year than patients treated by generalists [34].
Our results showed that only 3.33% of all prescriptions
were written by pulmonologists. This may, in part, be
because there are not enough pulmonologists to meet
the needs of the population in Taiwan. There were
only 700 pulmonologists in Taiwan at the end of 2002
(3 pulmonologists per 100,000 population) [36]. This
greatly restricts the access of patients to these
specialists.
The proportions of females treated with ISBAs and
ICSs were less than the proportions of males (odds
ratio, OR, 0.62, p < 0.001; OR, 0.65, p < 0.001) (Table 1).
This finding is consistent with a study by Roberts and
Bateman [37]. There was a similar trend for other anti-
asthmatic agents, except ketotifen. Females may be
treated less frequently with inhalers because they are
more likely to have an improper metered-dose inhaler
technique than males [38]. However, studies also show
that women, in general, take more prescription drugs
than men [39,40]. As a result, even though we have
shown that women used significantly less inhaled
anti-asthmatics than men in Taiwan, this may not have
any clinical significance.
International treatment guidelines indicate that
inhaled medications are preferred for elderly patients.
However, our results show that only 3.94% and 0.04%
of Taiwanese patients take ICSs and cromolyn,
respectively. Although excessive use of ISBAs is not
an issue among Taiwanese elderly patients with
asthma, many of  them take OSBAs and oral
bronchodilators, which may lead to severe side effects.
Physicians in Taiwan should prescribe more inhaled
anti-inflammatory agents, such as ICSs, in the treatment
of asthma in the elderly, as suggested in international
treatment guidelines.
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